Atopic Dermatitis and Hidradenitis Suppurativa: An Under-recognized Pair

Footnotes

Funding: none

Disclosures: VYS is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), a stock shareholder of Learn Health, and has served as an advisor, investigator and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt’s Bees, Dermira, Eli Lilly, Novartis, Pfizer, Galderma, Leo Pharma, SUN Pharma, Menlo Therapeutics, TARGET-DERM, GpSkin, and Skin Actives Scientific. JLH has served as an advisor for Novartis. Dr. Yosipovitch is a consultant and advisory board member for AbbVie, Bayer, Cervae, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Sienna and Trevi Therapeutics and is an investigator funded by Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Pfizer, Regeneron Pharmaceuticals, Inc., Sun Pharma. Dr Alavi has consulted for AbbVie, Janssen, Leo, Galderma, Novartis, Infla Rx, and Valeant, and is an investigator for AbbVie, Novartis, Regeneron, Pfizer, Boehringer Ingelheim, Glenmark, Merck Serono, Roche, Xoma, Infla Rx, UCB, and Xenon. Dr Alavi has also received a grant from AbbVie. The other authors have no relevant disclosures.

留言 (0)

沒有登入
gif